Liraglutide in the treatment of obesity

Bibliography

• Sassi F. Obesity and the economics of prevention: fit not fat. OECD Publishing; 2010
   Google Scholar
• Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378(9793):815-25
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. Why drugs? In: Wilding JH, editor. Pharmacotherapy of obesity. Birkhauser: Basel; 2008. p. 1-10
   Google Scholar
• Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988;962(3):308-16
   PubMed Web of Science ®Google Scholar
• LeBlanc E, O’Connor E, Whitlock EP, et al. Screening for and management of obesity and overweight in adults. Agency for Healthcare Research and Quality; Rockville, MD: 2011
   Google Scholar
• Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002;56(7):494-9
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61
   PubMed Web of Science ®Google Scholar
• Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59(2):151-84
   PubMed Web of Science ®Google Scholar
• Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother 2013;47(7-8):1007-16
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16(4):354-64
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308
   PubMed Web of Science ®Google Scholar
• Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann NY Acad Sci 2014;1311:1-13
   PubMed Web of Science ®Google Scholar
• Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg 2014;24(3):437-55
   PubMed Web of Science ®Google Scholar
• Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20(6):876-913
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101(3):515-20
   PubMed Web of Science ®Google Scholar
• Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23(3):304-11
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44(1):81-6
   PubMed Web of Science ®Google Scholar
• Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379(6560):69-72
   PubMed Web of Science ®Google Scholar
• Shirazi R, Palsdottir V, Collander J, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci USA 2013;110(40):16199-204
   PubMed Web of Science ®Google Scholar
• Information about Liraglutide. Available from: http://www.novonordisk.com/science/pipeline/liraglutide.asp
   Google Scholar
• Agerso H, Jensen LB, Elbrønd B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45(2):195-202
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84(10):3434-8
   PubMed Web of Science ®Google Scholar
• Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000;143(6):717-25
   PubMed Web of Science ®Google Scholar
• Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharm Sci 2013;102(8):2882-8
   PubMed Web of Science ®Google Scholar
• Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999;140(11):5356-63
   PubMed Web of Science ®Google Scholar
• Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25(8):1398-404
   PubMed Web of Science ®Google Scholar
• Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38(11):1944-53
   PubMed Web of Science ®Google Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide – the FDA’s review of a new antidiabetic therapy. N Engl J Med 2010;362(9):774-7
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151(4):1473-86
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36(6):843-54
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37(11):1443-51
   PubMed Web of Science ®Google Scholar
• Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014;38(5):689-97
   PubMed Web of Science ®Google Scholar
• Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med 2012;12(5):456-60
   PubMed Web of Science ®Google Scholar
• Levine HJ. Resting heart rate and life expectancy. J Am Coll Cardiol 1997;30(4):1104-6
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996;78(10):1175-6
   PubMed Web of Science ®Google Scholar
• Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens 2004;17(11 Pt 1):1005-10
   PubMed Web of Science ®Google Scholar
• Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986, doi:10.1136/bmjopen-2012-001986
   Google Scholar
• Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8(3):237-40
   PubMed Web of Science ®Google Scholar
• Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98(2):271-84
   PubMed Web of Science ®Google Scholar
• 2011. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm258826.htm
   Google Scholar
• Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32(5):834-8
   PubMed Web of Science ®Google Scholar
• Lambou-Gianoukos S, Heller SJ. Lithogenesis and bile metabolism. Surg Clin North Am 2008;88(6):1175-94. vii
   PubMed Web of Science ®Google Scholar
• Hegedüs L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96(3):853-60
   PubMed Web of Science ®Google Scholar
• Boland CL, Degeeter M, Nuzum DS, Tzefos M. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Ann Pharmacother 2013;47(4):490-505
   PubMed Web of Science ®Google Scholar
• Liraglutide for the treatment of type 2 diabetes mellitus. National Institute of Health and Clinical Excellence (NICE); 2010. Available from: http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf
   Google Scholar
• Tucker ME. Diabetes drug eyed as obesity treatment 2014. Available from: http://www.medscape.com/viewarticle/825697?src=rss
   Google Scholar
• World Health Organisation. Obesity and overweight. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
   Google Scholar